Genmab A/S (ETR:GE9)
293.60
+4.20 (1.45%)
At close: Jan 9, 2026
Genmab Employees
Genmab had 2,682 employees as of December 31, 2024. The number of employees increased by 478 or 21.69% compared to the previous year.
Employees
2,682
Change (1Y)
478
Growth (1Y)
21.69%
Revenue / Employee
€1,222,553
Profits / Employee
€503,327
Market Cap
17.99B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 2,682 | 478 | 21.69% |
| Dec 31, 2023 | 2,204 | 544 | 32.77% |
| Dec 31, 2022 | 1,660 | 448 | 36.96% |
| Dec 31, 2021 | 1,212 | 431 | 55.19% |
| Dec 31, 2020 | 781 | 233 | 42.52% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Siemens Aktiengesellschaft | 317,562 |
| Deutsche Telekom AG | 198,194 |
| Mercedes-Benz Group AG | 175,264 |
| Bayerische Motoren Werke Aktiengesellschaft | 159,104 |
| Allianz SE | 156,626 |
| SAP SE | 109,121 |
| Siemens Energy AG | 98,995 |
| Deutsche Bank Aktiengesellschaft | 89,753 |
Genmab News
- 2 days ago - Genmab: AI Partnership And Clinical Data Fuel Growth - Seeking Alpha
- 4 days ago - Why Are Investors Paying Attention To Genmab Stock? - Benzinga
- 4 days ago - Genmab A/S: Genmab Partners with Anthropic to Accelerate Research and Development Through Agentic Artificial Intelligence - Finanz Nachrichten
- 5 days ago - Genmab Partners with Anthropic to Accelerate Research and Development Through Agentic Artificial Intelligence - Business Wire
- 7 days ago - Genmab to Present at the 44th Annual J.P. Morgan Healthcare Conference - GlobeNewsWire
- 13 days ago - Genmab (GMAB) Ends Acasunlimab Development, Analysts Support Move - GuruFocus
- 13 days ago - Genmab Prunes Pipeline, Sharpens Focus On Late-Stage Cancer Assets - Benzinga
- 13 days ago - Genmab Prunes Pipeline, Sharpens Focus On Late-Stage Cancer Assets - Benzinga